FDA OK's Omeros cataract surgery drug Omidria; eyes on pricing
This article was originally published in Scrip
Executive Summary
With the FDA's approval in hand for Omidria (phenylephrine and ketorolac injection) for use during cataract surgery or intraocular lens replacement (ILR), all eyes are now on the drug's pricing and launch, which is anticipated late summer or early fall.